Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2020 Filed May 14, 2020 20:46 UTC |
PARSHALL B LYNNEDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000091 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:46 UTC |
WIERENGA WENDALLDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000093 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:46 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000092 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:46 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000090 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:45 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000089 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:45 UTC |
GAGE L PATRICKDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000088 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:45 UTC |
Califf RobertDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000086 · edgardoc.xml · derivative · entry 1 Califf Robert · CIK 0001574557 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,666 | $19.47 Strike: $15.24 | $129,787.02 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · derivative · entry 9 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,666 shares Expires 2020-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $19.47 Strike: $8.64 | $64,893.51 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · derivative · entry 8 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $20.00 Strike: $6.21 | $400,006.00 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · derivative · entry 7 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 6,666 | $19.47 | $129,787.02 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 6 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 6,666 | $15.24 | $101,589.84 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 5 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 3,333 | $19.47 | $64,893.51 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 4 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 3,333 | $8.64 | $28,797.12 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 3 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 20,000 | $20.00 | $400,006.00 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 2 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:22 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 20,000 | $6.21 | $124,200.00 |
DisclosureSEC source: 0001061983-20-000077 · edgardoc.xml · nonDerivative · entry 1 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $17.00 Strike: $6.78 | $70,822.00 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · derivative · entry 6 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $17.00 Strike: $5.46 | $70,822.00 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · derivative · entry 5 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 4,166 | $17.00 | $70,822.00 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · nonDerivative · entry 4 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 4,166 | $5.46 | $22,746.36 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · nonDerivative · entry 3 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
SaleCommon Stock | 4,166 | $17.00 | $70,822.00 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · nonDerivative · entry 2 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 05, 2020 Filed May 6, 2020 18:39 UTC |
COSTA SANTO JDirector
|
Exercise / conversionCommon Stock | 4,166 | $6.78 | $28,245.48 |
DisclosureSEC source: 0001061983-20-000075 · edgardoc.xml · nonDerivative · entry 1 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 1, 2020 23:06 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 5,000 | $14.34 | $71,678.00 |
DisclosureSEC source: 0001061983-20-000073 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,444 F1 · shares: 5,000 shares disposed of is comprised of: (i) 908 shares of common stock purchased on 10/31/2016 pursuant to the Employee Stock Purchase Plan of Cytokinetics, Incorporated (the ?ESPP?), (ii) 795 shares of common stock purchased on 10/31/2017 pursuant to the ESPP, (iii) 859 shares of common stock purchased on 10/31/2018 pursuant to the ESPP, (iv) 1,117 shares of common stock purchased on 4/28/2017 pursuant to the ESPP, and (v) 1,321 shares of common stock purchased on 4/30/2018 pursuant to the ESPP. F2 · balance_after: Includes 8,846 shares of common stock purchased pursuant to the ESPP. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,666 | $16.00 Strike: $11.04 | $106,656.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · derivative · entry 6 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,666 shares Expires 2021-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $16.00 Strike: $8.64 | $53,328.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · derivative · entry 5 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
SaleCommon Stock | 6,666 | $16.00 | $106,656.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 4 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
Exercise / conversionCommon Stock | 6,666 | $11.04 | $73,592.64 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
SaleCommon Stock | 3,333 | $16.00 | $53,328.00 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 22:25 UTC |
WIERENGA WENDALLDirector
|
Exercise / conversionCommon Stock | 3,333 | $8.64 | $28,797.12 |
DisclosureSEC source: 0001061983-20-000071 · edgardoc.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Wong RobertVP, Chief Accounting Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,410 | $14.40 Strike: $14.40 | $207,504.00 |
DisclosureSEC source: 0001061983-20-000065 · edgardoc.xml · derivative · entry 3 Wong Robert · CIK 0001777562 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,410 Underlying: Common Stock · 14,410 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Wong RobertVP, Chief Accounting Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 5,590 | $14.40 Strike: $14.40 | $80,496.00 |
DisclosureSEC source: 0001061983-20-000065 · edgardoc.xml · derivative · entry 2 Wong Robert · CIK 0001777562 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,590 Underlying: Common Stock · 5,590 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Wong RobertVP, Chief Accounting Officer
|
GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000065 · edgardoc.xml · nonDerivative · entry 1 Wong Robert · CIK 0001777562 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,004 F1 · balance_after: Includes up to 3004 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
SCHLOSSBERG MARK ASVP - Legal & General Counsel
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,393 | $14.40 Strike: $14.40 | $725,659.20 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · derivative · entry 3 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,393 Underlying: Common Stock · 50,393 shares Expires 2030-03-05 F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
SCHLOSSBERG MARK ASVP - Legal & General Counsel
|
GrantIncentive Stock Option (right to buy) · Derivative | 9,607 | $14.40 Strike: $14.40 | $138,340.80 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · derivative · entry 2 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,607 Underlying: Common Stock · 9,607 shares Expires 2030-03-05 F1 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
SCHLOSSBERG MARK ASVP - Legal & General Counsel
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000064 · edgardoc.xml · nonDerivative · entry 1 SCHLOSSBERG MARK A · CIK 0001520533 · SVP - Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 79,146 | $14.40 Strike: $14.40 | $1,139,702.40 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,146 Underlying: Common Stock · 79,146 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantIncentive Stock Option (right to buy) · Derivative | 10,854 | $14.40 Strike: $14.40 | $156,297.60 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,854 Underlying: Common Stock · 10,854 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,621 F1 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Cragg DavidSVP Human Resources
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,408 | $14.40 Strike: $14.40 | $725,875.20 |
DisclosureSEC source: 0001061983-20-000062 · edgardoc.xml · derivative · entry 3 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,408 Underlying: Common Stock · 50,408 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Cragg DavidSVP Human Resources
|
GrantIncentive Stock Option (right to buy) · Derivative | 9,592 | $14.40 Strike: $14.40 | $138,124.80 |
DisclosureSEC source: 0001061983-20-000062 · edgardoc.xml · derivative · entry 2 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,592 Underlying: Common Stock · 9,592 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC |
Cragg DavidSVP Human Resources
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000062 · edgardoc.xml · nonDerivative · entry 1 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,098 F1 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Jaw ChingSVP Finance & CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,408 | $14.40 Strike: $14.40 | $725,875.20 |
DisclosureSEC source: 0001061983-20-000061 · edgardoc.xml · derivative · entry 3 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,408 Underlying: Common Stock · 50,408 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Jaw ChingSVP Finance & CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 9,592 | $14.40 Strike: $14.40 | $138,124.80 |
DisclosureSEC source: 0001061983-20-000061 · edgardoc.xml · derivative · entry 2 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,592 Underlying: Common Stock · 9,592 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Jaw ChingSVP Finance & CFO
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000061 · edgardoc.xml · nonDerivative · entry 1 Jaw Ching · CIK 0001710875 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,165 F1 · balance_after: Includes up to 513 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Blum Robert IDirector · President & CEO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 231,175 | $14.40 Strike: $14.40 | $3,328,920.00 |
DisclosureSEC source: 0001061983-20-000060 · edgardoc.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,175 Underlying: Common Stock · 231,175 shares Expires 2030-03-05 F4 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Blum Robert IDirector · President & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 8,825 | $14.40 Strike: $14.40 | $127,080.00 |
DisclosureSEC source: 0001061983-20-000060 · edgardoc.xml · derivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,825 Underlying: Common Stock · 8,825 shares Expires 2030-03-05 F4 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:32 UTC |
Blum Robert IDirector · President & CEO
|
GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000060 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,444 F1 · balance_after: Includes up to 8,846 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| March 06, 2020 Filed Mar 20, 2020 19:21 UTC |
GAGE L PATRICKDirector
|
SaleCommon Stock | 8,000 | $14.82 | $118,592.00 |
DisclosureSEC source: 0001061983-20-000069 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:45 UTC |
Blum Robert IDirector · President & CEO
|
Tax withholdingCommon Stock | 4,150 | $13.94 | $57,851.00 |
DisclosureSEC source: 0001061983-20-000052 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,444 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 8,846 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:44 UTC |
Cragg DavidSVP Human Resources
|
Tax withholdingCommon Stock | 1,384 | $13.94 | $19,292.96 |
DisclosureSEC source: 0001061983-20-000051 · edgardoc.xml · nonDerivative · entry 1 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,098 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 11,616 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.